Biopharmas in Asia-Pacific raising money in public or private financings: Bugworks Research, Ethris, Linkinvax, Merck, Statera, TC, Teclison, Ucello.

Med-tech firms raising money in public or private financings, including: Companion Spine, Memora, Newton Biocapital, Oxdx.

Kallyope Inc., a company leveraging connections between the gut and brain to develop new medicines for diabetes, obesity and other diseases, has raised $236 million in series D financing to support its work. Readouts of early clinical data for its most advanced programs, phase I small molecules for metabolic disease and gut barrier conditions, will start to arrive later this year, company CEO and President Jay Galeota told BioWorld.

LONDON – Neuromuscular disease specialist NMD Pharma A/S has raised €35 million (US$39.7 million) in a new financing, as it awaits initial data from its first clinical trial, in the treatment of myasthenia gravis. The new money enables NMD to complete that phase IIa study and to launch another trial of the same compound, NMD-670, in spinal muscular atrophy. The Aarhus, Denmark-based company is preparing the IND and aims to treat the first patient before the end of 2022.

Biopharmas raising money in public or private financings, including: Genesis, Imidomics, Marinomed, Renibus, Sunshine, Terray, Vera.

Med-tech firms raising money in public or private financings, including: Cognetivity, Variantyx.

Biopharmas raising money in public or private financings, including: Teclison.

Med-tech firms raising money in public or private financings, including: Bodymatter, Ortho Regenerative Technologies.

Biopharmas raising money in public or private financings, including: Adial, Aeglea, Alzecure, Enveric, Ortho Regenerative Technologies, TC, Ucello.